



Liste modèle des médicaments essentiels



Anti-D immunoglobulin [Informations générales](#)

Section

Human immunoglobulins

- Parenteral > General injections > IV: 250 µg in single-dose vial
- Parenteral > General injections > IM: 250 µg in single-dose vial

Indications

[Maternal care for red cell antibodies Rh incompatibility reaction](#)



Anti-rabies immunoglobulin [Informations générales](#)

Section

Human immunoglobulins

- Parenteral > General injections > IM: 150 IU per mL in vial
- Parenteral > Locoregional injections > Other: 150 IU per mL in vial

Indications

[Rabies](#)



Anti-tetanus immunoglobulin [Informations générales](#)

Section

Human immunoglobulins

- Parenteral > General injections > IM: 500 IU in vial

Indications

[Tetanus](#)



C1 esterase inhibitor [Informations générales](#)

Section

Human immunoglobulins

- Parenteral > General injections > IV: 500 IU in vial powder for injection

Indications

[Hereditary angioedema](#)



Coagulation factor IX complex [Informations générales](#)

Section

Coagulation factors

Indications

Therapeutic equivalent to [coagulation factor IX, plasma-derived](#) pour [Coagulation defects, purpura or other haemorrhagic or related conditions](#) Therapeutic equivalent to [coagulation factor IX, plasma-derived](#) pour [Haemophilia B](#)

Coagulation factor IX, plasma-derived [Informations générales](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

[Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B](#)

Coagulation factor IX, recombinant [Informations générales](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

[Haemophilia B](#)

Coagulation factor VIII, plasma-derived [Informations générales](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

[Haemophilia A](#)

Coagulation factor VIII, recombinant [Informations générales](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

[Haemophilia A](#)

Cryoprecipitate (native) [Informations générales](#)

Section

Blood and blood components

Indications

Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) pour [Coagulation defects, purpura or other haemorrhagic or related conditions](#) Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) pour [Obstetric haemorrhage](#) Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) pour [Haemophilia A](#) Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) pour [Von Willebrand disease](#)

Cryoprecipitate (pathogen-reduced) [Informations générales](#)

Section

Blood and blood components

- Injection: frozen liquid in bag or lyophilized powder in vial containing:
 - > 50 IU Factor VIII
 - > 100 IU vWF
 - > 140 mg clottable fibrinogen per unit

Indications

[Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage Haemophilia A Von Willebrand disease](#)

Dextran 40 [Informations générales](#)

Section
Plasma substitutes

◦ .

Indications
[Hypovolaemia](#)

Dextran 70 [Informations générales](#)

Section
Plasma substitutes

- Parenteral > General injections > IV: 6% injectable solution

Indications
[Hypovolaemia](#)

Fresh-frozen plasma [Informations générales](#)

Section
Blood and blood components

- Parenteral > General injections > IV:

Indications
[Blood transfusion without reported diagnosis](#)

Normal immunoglobulin [Informations générales](#)

Section
Human immunoglobulins

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution
- Parenteral > General injections > IM: 16% protein solution
- Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications
[Primary immunodeficiencies Mucocutaneous lymph node syndrome Langerhans cell histiocytosis](#)

Platelets [Informations générales](#)

Section
Blood and blood components

- Parenteral > General injections > IV:

Indications
[Blood transfusion without reported diagnosis](#)

Polygeline [Informations générales](#)

Section
Plasma substitutes

- Parenteral > General injections > IV: 3.5% injectable solution
- Parenteral > General injections > IV: 3.5% in solution

Indications
Therapeutic equivalent to [dextran 70](#) pour [Hypovolaemia Hypovolaemia](#)

Red blood cells [Informations générales](#)

Section
Blood and blood components

- Parenteral > General injections > IV:

Indications
[Blood transfusion without reported diagnosis](#)

Whole blood [Informations générales](#)

Section
Blood and blood components

- Parenteral > General injections > IV:

Indications
[Blood transfusion without reported diagnosis](#)